KZIA
Kazia Therapeutics Limited
There isn't enough reported data to score KZIA yet.
KZIA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
KZIA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
KZIA PE Valuation
KZIA has no meaningful PE right now: it lost money over the past year.
KZIA Forward outlook
There aren't enough analyst estimates for KZIA to show an outlook.
KZIA Earnings Per Share
KZIA Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2021 | -59% | N/A |
| Q2 2018 | -5331% | N/A |
KZIA Free Cash Flow
KZIA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +296K shares |
KZIA Net Leverage
KZIA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
KZIA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.1 | Neutral |
| Stochastic | 8.7 | Oversold |
KZIA's weekly RSI is 35 (neutral) and its Stochastic is 9 (oversold).
KZIA PE vs Healthcare Sector
KZIA has no meaningful PE right now: it lost money over the past year.
KZIA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.18 | 15% below |
| 20 week MA | $10.9 | 36% below |
| 50 week MA | $10.2 | 32% below |
| 100 week MA | $8.61 | 19% below |
| 200 week MA | $20.7 | 66% below |
KZIA is in a downtrend: it's below all five of its weekly moving averages, and 66% below its 200-week average.
KZIA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $223.3 | $451.5 | +102% |
| 2021 | $451.5 | $419.5 | -7.1% |
| 2022 | $419.5 | $27.2 | -94% |
| 2023 | $27.2 | $22.0 | -19% |
| 2024 | $22.0 | $15.4 | -30% |
| 2025 | $15.4 | $7.57 | -51% |
| 2026 YTD | $7.57 | $6.95 | -8.2% |
KZIA has finished five years in a row lower, and it's down 8.2% so far in 2026.